European Journal of Clinical Pharmacology

, Volume 33, Issue 3, pp 249–254 | Cite as

Effect of captopril on renin and blood pressure in cirrhosis

  • B. Stanek
  • F. Renner
  • A. Sedlmayer
  • K. Silberbauer
Originals

Summary

In hepatic cirrhosis neurohumoral vasoconstrictor systems are activated to compensate for circulatory disturbances. To study the renin-angiotensin-aldosterone system in more detail, angiotensin converting enzyme in 15 patients with advanced liver disease was inhibited with captopril after moderate sodium restriction.

Captopril caused an increase in plasma renin activity (p<0.005) and a decrease in plasma aldosterone (p<0.025) from an elevated baseline, and a moderate drop in systolic (p<0.025) and diastolic (p<0.05) blood pressure. Hyperreninaemia after captopril was inversely related to the prevailing plasma sodium level (r=−0.66,p<0.01), and the changes in both systolic and diastolic blood pressure were correlated with baseline plasma renin activity (r=0.49,p<0.05 for systolic andr=0.71,p<0.01 for diastolic blood pressure). No change occurred in heart rate or in stimulated plasma noradrenaline and vasopressin levels.

The data suggest that in these cirrhotic patients the reactivity of the renin-angiotensin-aldosterone system was still intact, although it occurred at a higher level. They confirm the importance of the renin-angiotensin-aldosterone system in arterial blood pressure regulation in cirrhosis.

Key words

liver cirrhosis captopril renin-angiotensin system blood pressure aldosterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Skorecki KL, Brenner BM (1982) Body fluid homeostasis in congestive heart failure and cirrhosis with ascites. Am J Med 72: 323–338Google Scholar
  2. 2.
    Epstein M (1982) The renin angiotensin system in liver disease. In: Epstein M (ed) The kidney in liver disease, 2nd edn. Elsevier, New York, pp 353–375Google Scholar
  3. 3.
    Bichet D, Vicky J, Van Putten BS, Schrier RW (1982) Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 307: 1552–1557Google Scholar
  4. 4.
    Ring H, Hesse B, Henricksen JH, Christensen NJ (1982) Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: Plasma norepinephrine concentration, hepatic extraction and renal release. Hepatology 3: 304–310Google Scholar
  5. 5.
    Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW (1982) Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Int Med 96: 413–417Google Scholar
  6. 6.
    Epstein M, Weitzmann RE, Preston S, Denunzio AG (1984) Relationship between plasma arginine vasopressin and renal water handling in decompensated cirrhosis. Miner Electrolyte Metab 10: 155–165Google Scholar
  7. 7.
    Epstein M, Lifschitz M, Ramachandran M, Rappaport K (1982) Characterization of renal prostaglandin E2-responsiveness in decompensated cirrhosis: Implications for renal sodium handling. Clin Sci 63: 555–563Google Scholar
  8. 8.
    Arroyo V, Planas R, Gaya J, Deulofeu R, Rimola A, Perez-Ayuso M, Rivera F, Rodes J (1983) Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 13: 271–278Google Scholar
  9. 9.
    Dzau VJ, Packer M, Lilly SL, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin angiotensin system and to hyponatremia. N Engl J Med 310: 347–352Google Scholar
  10. 10.
    Saruta T, Eguchi T, Saltio I (1983) Angiotensin antagonists in liver disease. In: Epstein M (ed) The kidney in liver disease. Elsevier, New York, Biomedical, pp 441–500Google Scholar
  11. 11.
    Pariente EA, Bataille C, Berkoff E, Lebrec D (1985) Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology 88: 1255–1259Google Scholar
  12. 12.
    Passon PG, Peuler JD (1983) A simplified radiometric assay for norepinephrine and epinephrine. Analyt Biochem 51: 618–631Google Scholar
  13. 13.
    Keller U, Berger PG, Bühler FR, Stauffacher W (1984) Role of the splanchnic bed in extracting circulating adrenaline and noradrenaline in normal subjects and in patients with cirrhosis of the liver. Clin Sci 67: 45–49Google Scholar
  14. 14.
    Arroyo V, Bosch J, Mauri M, Viver J, Mas A, Rivera F, Rodes J (1979) Renin aldosterone and renal hemodynamics in cirrhotics with ascites. Eur J Clin Invest 9: 69–73Google Scholar
  15. 15.
    Schröder ET, Anderson GH, Goldman SH, Streeten DHP (1976) Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 9: 511–519Google Scholar
  16. 16.
    Mashford ML, Mahon WA, Chalmers TC (1962) Studies of the cardiovascular system in the hypotension of liver failure. N Engl J Med 167: 1071–1074Google Scholar
  17. 17.
    Henriksen JH, Christensen NJ, Ring-Larsen H (1981) Noradrenaline and adrenaline concentrations in various vascular beds in patients with cirrhosis. Relation to hemodynamics. Clin Physiol 1: 293–304Google Scholar
  18. 18.
    Packer M, Medina N, Yushak M (1984) Efficacy of captopril in low renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. Am J Cardiol 54: 771–777Google Scholar
  19. 19.
    Epstein M, Levinson R, Sancho J, Haber E, Re R (1977) Characterization of the renin aldosterone system in decompensated cirrhosis. Circ Res 41: 818–829Google Scholar
  20. 20.
    Arroyo V, Bosch J, Mauri M, Rivera F, Nawarro-Lopez F, Rodes J (1981) Effect of angiotensin II blockade on systemic and hepatic hemodynamics and on the renin angiotensin aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11: 221–229Google Scholar
  21. 21.
    Bosh J, Arroyo V, Rodes J (1983) Hepatic and systemic hemodynamics and the renin-angiotensin-System in cirrhosis. In: Epstein M (ed) The kidney in liver disease, 2nd edn. Elsevier, New York, pp 423–439Google Scholar
  22. 22.
    Laragh JH, Case DB, Atlas SA, Sealy JE (1980) Captopril compared with other antirenin system agents in hypertensive patients. Its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 2: 586–591Google Scholar
  23. 23.
    Levine TB, Franciosa JA, Cohn JN (1980) Acute and long-term response to an oral converting enzyme inhibitor, captopril, in congestive heart failure. Circulation 62: 35–39Google Scholar
  24. 24.
    De Jonge A, Wilfert B, Kalkmann HO, Thoolen MJMC, van Meel JCA, Timmermanns PBMWM, van Zwieten PA (1982) Effect of captopril on the regulation of noradrenaline release in the heart and vascular smooth muscle of the pithed rat. Br J Pharmacol 75: 134 pGoogle Scholar
  25. 25.
    Perez-Ayuso RM, Arroyo V, Camps J, Rimola A, Gaya J, Costa J, Rivera J, Rodes J (1984) Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 26: 72–80Google Scholar
  26. 26.
    Möhring J, Glanzner K, Muriel JA, Dusing R, Kramer HJ, Arbogast R, Koch-Weser J (1980) Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiol Pharmacol 2: 367–376Google Scholar
  27. 27.
    Cowley AW, Quillen EW, Skelton MM (1983) Role of vasopressin in cardiovascular regulation. Fed Proc 42: 3170–3176Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • B. Stanek
    • 1
  • F. Renner
    • 2
  • A. Sedlmayer
    • 2
  • K. Silberbauer
    • 1
    • 3
  1. 1.2nd Department of Internal MedicineUniversity of ViennaViennaAustria
  2. 2.2nd Department of Gastroenterology and Hepatology, Ludwig Boltzmann-Institute for Clinical EndocrinologyUniversity of ViennaViennaAustria
  3. 3.Krankenhaus der Barmherzigen BrüderEisenstadtAustria

Personalised recommendations